Tyra Biosciences Reports Q1 Results, Extends Cash Runway to H2 2028 with $147.9M ATM Proceeds
TYRA has more than doubled off its 52-week low of $8.75.
Summary
Tyra Biosciences filed its Q1 2026 report, detailing an extended cash runway into the second half of 2028, supported by $147.9 million in net proceeds from its at-the-market offering program.
Key Events · Earnings and Guidance · TYRA
-
Cash Runway Extended
The company's cash, cash equivalents, and marketable securities of $383.5 million as of March 31, 2026, are projected to fund operations into the second half of 2028, extending the previous guidance of 'at least 2027'.
-
ATM Offering Nearly Fully Utilized
Tyra Biosciences raised $147.9 million in net proceeds during Q1 2026 by selling 4,690,532 shares through its $150 million at-the-market (ATM) offering program, which was established in May 2025.
-
Increased Operating Expenses
Research and development expenses increased to $33.5 million in Q1 2026 from $25.0 million in Q1 2025, and general and administrative expenses rose to $8.5 million from $6.9 million, reflecting ongoing pipeline advancement.
-
Net Loss Widened
The company reported a net loss of $39.3 million for Q1 2026, compared to a net loss of $28.1 million for the same period in 2025.
Analysis · TYRA · Life Sciences
This quarterly report provides the detailed financial results for Q1 2026, confirming the company's cash, cash equivalents, and marketable securities of $383.5 million are sufficient to fund operations into the second half of 2028. This extends the previously disclosed runway of 'through at least 2027' from the last 10-K. The improved liquidity is largely due to the utilization of its at-the-market (ATM) offering program, which generated $147.9 million in net proceeds during the quarter, nearly exhausting the $150 million program. While the company reported an increased net loss of $39.3 million and higher operating expenses, these reflect continued investment in its clinical pipeline. Several executives also adopted routine 10b5-1 trading plans during the quarter, which are pre-planned arrangements and not indicative of immediate insider selling.
At the time of this filing, TYRA was trading at $34.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $8.75 to $40.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.